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CLINICAL RESEARCH
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Moustafa A. Moustafa6, Tak Mao Chan7, Anatole Besarab8, Willis Chou9, Charles Bradley9,
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Introduction: Roxadustat is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor that stimulates
erythropoiesis and improves iron metabolism. We assessed the efﬁcacy and tolerability of roxadustat in
patients with chronic kidney disease (CKD)-related anemia not on dialysis.
Methods: ANDES was a global Phase 3 randomized study in which adults with stage 3–5 CKD not on
dialysis received roxadustat or placebo. Patients were initially dosed thrice weekly; dose was titrated to
achieve a hemoglobin level $11.0 g/dl, followed by titration for maintenance. The primary endpoints were
change in hemoglobin (weeks 28–52) and proportion of patients achieving a hemoglobin response
(hemoglobin $11.0 g/dl and increase $1.0 g/dl [baseline >8.0 g/dl], or increase $2.0 g/dl [baseline #8.0 g/
dl]) (week 24). Treatment-emergent adverse events (TEAEs) and serious adverse events (TESAEs) were
recorded.
Results: In roxadustat (n ¼ 616) and placebo (n ¼ 306) groups, hemoglobin mean (SD) change from
baseline over weeks 28–52 was signiﬁcantly larger for roxadustat (2.00 [0.95]) versus placebo (0.16 [0.90]),
corresponding to least-squares mean difference of 1.85 g/dl (95% conﬁdence interval [CI] 1.74–1.97; P <
0.0001). The proportion of patients achieving a response at week 24 was larger for roxadustat (86.0%; 95%
CI 83.0%–88.7%) versus placebo (6.6%; 95% CI 4.1%–9.9%; P < 0.0001). The proportion of patients
receiving rescue therapy at week 52 was smaller for roxadustat (8.9%) versus placebo (28.9%); hazard
ratio, 0.19 (95% CI 0.14–0.28; P < .0001). The incidences of TEAEs and TESAEs were comparable.
Conclusion: This study showed that roxadustat corrected and maintained hemoglobin and was well
tolerated in patients with CKD-related anemia not on dialysis (ClinicalTrials.gov NCT01750190).
Kidney Int Rep (2021) 6, 624–635; https://doi.org/10.1016/j.ekir.2020.11.034
KEYWORDS: anemia; chronic kidney disease; rescue therapy; roxadustat
ª 2020 International Society of Nephrology. Published by Elsevier Inc. This is an open access article under the CC BYNC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

See Commentary on Page 559

n patients with non–dialysis-dependent CKD (NDDCKD), anemia is a common complication with
increasing prevalence as CKD progresses, with nearly
50% of patients with stage 5 CKD having anemia.1,2
The severity of anemia is associated with an increased
risk for cardiovascular disease and death.3,4 The
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current treatment for CKD-related anemia includes oral
or intravenous (i.v.) iron supplementation, red blood
cell (RBC) transfusions, and/or treatment with an
erythropoiesis-stimulating agent (ESA) administered
subcutaenously.5
Studies demonstrate more cardiovascular events and
higher mortality rates among patients with CKD randomized to higher target hemoglobin levels with
ESAs,6–8 and consequently these products carry black
box safety warnings.9,10 Subsequent analyses demonstrated higher ESA doses, rather than achieved hemoglobin, were associated with higher risk.11 Safer and
simpler treatments for CKD-related anemia are needed.
Kidney International Reports (2021) 6, 624–635
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Randomizaon

Roxadustat (TIW), n=616
ICF and BL
Assessments

EOT or ET
Assessments

2:1

EOS
Assessments

Placebo (TIW), n=306
Up to 6 weeks before
ﬁrst dose of treatment

52 weeks minimum, up to 3 years

4 weeks aer last dose
of treatment or ET

Screening

Treatment

Follow-up

Figure 1. Study design. BL, baseline; EOS, end of study; EOT, end of treatment; ET, early termination; ICF, informed consent form; TIW, thrice
weekly.

Anemia pathogenesis is multifactorial, and includes
impaired oxygen-dependent regulation of erythropoiesis
due to inadequate production of erythropoietin.12–14
Hypoxia-inducible factor (HIF) is part of a system in
which the prolyl hydroxylases sense oxygen15 and is
key to erythropoietic response. Roxadustat is an oral HIF
prolyl hydroxylase inhibitor that stimulates
erythropoiesis and improves iron metabolism. HIF stabilizers have been approved for the treatment of
CKD-related anemia in China and Japan, including roxadustat, which has been approved in China16,17 and
Japan to treat anemia in patients with dialysis-dependent
CKD and NDD-CKD.18
We evaluated the efﬁcacy and safety of roxadustat
versus placebo for the treatment of CKD-related anemia
in patients with NDD-CKD.19,20

METHODS
Trial Design and Patients
This randomized, double-blind, placebo-controlled,
Phase 3 study evaluated the efﬁcacy and safety of
roxadustat in patients with NDD-CKD and CKD-related
anemia (ClinicalTrials.gov number, NCT01750190)
(Figure 1). The study was conducted at 163 sites in the
United States, South America, Australia, New Zealand,
and Asia.
The study protocol was approved by institutional
review boards and/or ethics committees. All patients
provided informed consent. The study was conducted
in accordance with the Declaration of Helsinki21 and
International Council for Harmonisation guidelines for
Good Clinical Practice.22
Eligible patients were $18 years; had a diagnosis of
stage 3–5 CKD23 and not on dialysis, with an estimated
glomerular ﬁltration rate (eGFR) <60 ml/min per 1.73
m2; baseline hemoglobin #10.0 g/dl, ferritin $30 ng/
ml, and transferrin saturation (TSAT) $5%. Key
exclusion criteria included any ESA treatment, >1 i.v.
iron dose, major cardiovascular event within 12 weeks
of randomization, and RBC transfusion within 8 weeks
of randomization. Complete criteria are listed in
Kidney International Reports (2021) 6, 624–635

Supplementary Table S1 and sample size determination
methods are described in the Supplementary Material.
Randomization and Dosing Procedures
Patients were randomly assigned (2:1) to receive oral
roxadustat or matching placebo in a double-blinded
manner. Randomization schedules were prospectively
prepared, and automated randomization and treatment
assignments were provided by an interactive web
response system. Randomization was stratiﬁed by
screening hemoglobin (#8.0 vs. >8.0 g/dl); history of
cardiovascular, cerebrovascular, or thromboembolic
diseases; eGFR (<30 vs. $30 ml/min per 1.73 m2); and
region (US vs. countries outside US).
All patients were initially dosed thrice weekly based
on body weight. Patients weighing 45 to <70 kg
received 70 mg roxadustat or placebo, and those
weighing $70 kg received 100 mg thrice weekly. The
investigator, study site staff, patient, sponsor, and
designees were all blinded to the study drug assignment, but not the dose, which was achieved by using
identical roxadustat and placebo tablets. Additional
dosing details are provided in Supplementary Table S2.
Efﬁcacy Assessments
The primary efﬁcacy endpoints were change in hemoglobin from baseline averaged over weeks 28 to 52
regardless of rescue therapy (US Food and Drug
Administration submission) and the proportion of patients achieving a hemoglobin response at 2 consecutive visits $5 days apart during the ﬁrst 24 weeks
without rescue therapy (EU European Medicines
Agency submission). A hemoglobin response was
deﬁned as hemoglobin $11.0 g/dl and an increase
of $1.0 g/dl in patients with baseline >8.0 g/dl, or
hemoglobin increase $2.0 g/dl in patients with
baseline #8.0 g/dl. Rescue therapy included blood/RBC
transfusion, ESA treatment, or i.v. iron. Oral iron was
encouraged. Secondary efﬁcacy endpoints are listed in
Supplementary Table S3.
Additional, exploratory efﬁcacy endpoints
included the following: mean change from baseline
in hemoglobin during weeks 28–36 by baseline iron
625
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Paents screened: 1672

Did not meet inclusion/
exclusion criteria: 750

Paents randomized: 922

Roxadustat: 616 (ITT)

Disconnuaons
AE or death
Consent withdrawn
Lost to follow-up
Physician decision
Protocol deviaon
Study/site terminated
Lack of eﬃcacy*
Other

267 (43.3%)
85 (13.8%)
83 (13.5%)
28 (4.5%)
16 (2.6%)
6 (1.0%)
4 (0.6%)
2 (0.3%)
43 (7.0%)

Placebo: 306 (ITT)

Disconnuaons
Consent withdrawn
Lack of eﬃcacy*
AE or death
Physician decision
Lost to follow-up
Protocol deviaon
Study/site terminated
Other

208 (68.0%)
89 (29.1%)
43 (14.1%)
30 (9.8%)
17 (5.6%)
7 (2.3%)
5 (1.6%)
1 (0.3%)
16 (5.2%)

Completed treatment: 349 (56.7%)

Completed treatment: 98 (32.0%)

Completed EOS visit: 340 (55.2%)

Completed EOS visit: 95 (31.0%)

Parcipated in LTFU†: 96 (15.6%)

Parcipated in LTFU†: 96 (31.4%)

Figure 2. CONSORT ﬂow diagram. *Including ESA rescue. †Patients who discontinued from the study and participated in the LTFU were
evaluated for cardiovascular events of interest, vital status, and hospitalizations after EOS until study closure. AE, adverse event; EOS, end of
study; ESA, erythropoiesis-stimulating agent; LTFU, long-term follow-up.

status regardless of rescue therapy; mean changes
from baseline in serum hepcidin, iron, and other
iron-related parameters, including ferritin, TSAT,
and total iron-binding capacity (TIBC), total
cholesterol, and low-density lipoprotein (LDL)/highdensity lipoprotein ratio at each scheduled visit to
week 52.
Safety
Safety measures included TEAEs and TESAEs, laboratory measures, vital signs, and electrocardiograms.
Statistical Analysis
For the US Food and Drug Administration primary
endpoint, a missing-at-random-based multiple imputation analysis of covariance model tested the null hypothesis that hemoglobin changes from baseline
averaged over weeks 28 to 52 regardless of rescue
therapy were comparable in roxadustat and placebo
patients in the intent-to-treat (ITT) population (all
randomized patients). For the EU European Medicines
Agency primary endpoint, a Cochran-Mantel-Haenszel
626

model tested the null hypothesis that the percentage of
patients achieving a hemoglobin response without
rescue therapy would be comparable in roxadustat and
placebo patients in the full analysis set (FAS; all randomized patients who received $1 dose of study drug
with baseline and $1 post-dose hemoglobin). The
Cochran-Mantel-Haenszel model was adjusted for
stratiﬁcation factors (see Supplementary Material). For
both US and EU endpoints, the 2-sided alpha level of
signiﬁcance was P < 0.05.
For primary endpoints, sensitivity analyses were
performed on multiple patient subgroups (see
Supplementary Material). An analysis using multiple
imputations was prespeciﬁed as a sensitivity analysis.
Secondary efﬁcacy endpoints were analyzed using a
ﬁxed-sequence approach to adjust for multiplicity
testing. If the null hypothesis was rejected, the superiority/noninferiority of roxadustat versus placebo was
accepted, and testing progressed to the next endpoint
(Supplementary Table S3).
The safety population included all randomized patients who received $1 dose of study drug. If the
Kidney International Reports (2021) 6, 624–635
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Table 1. Baseline demographic and clinical characteristics (intent
to treat)
Characteristic
Mean (SD) age, y
Median (range) age, y

Roxadustat
(n [ 616)

Placebo
(n [ 306)

64.9 (12.6)

64.8 (13.2)

66 (22–94)

66 (22–91)

Age group, n (%)
18–64

271 (44.0)

65–74

192 (31.2)

146 (47.7)
79 (25.8)

$75

153 (24.8)

81 (26.5)

Female gender, n (%)

375 (60.9)

176 (57.5)

Mean (SD) BMI, kg/m2

27.4 (6.3)

27.3 (6.0)

Mean (SD) hemoglobin (g/dl)a

9.10 (0.75)

9.09 (0.69)

52 (8.4)

23 (7.5)

Hemoglobin (g/dl) cohort, n (%)
#8.0
>8.0 to #9.0

173 (28.1)

97 (31.7)

>9.0

391 (63.5)

186 (60.8)

21.9 (11.5)

22.4 (11.4)

Mean (SD) eGFR (ml/min per 1.73 m2)
eGFR (ml/min/1.73 m2)b cohort, n (%)
<10

71 (11.5)

19 (6.2)

10 to <15

124 (20.1)

76 (24.8)

15 to <30

292 (47.4)

146 (47.7)

30 to <45

96 (15.6)

46 (15.0)

45 to <60

31 (5.0)

18 (5.9)

2 (0.3)

1 (0.3)

Replete: Ferritin $100 ng/ml and
TSAT $20%

373 (60.6)

170 (55.6)

Not replete: Ferritin <100 ng/ml or
TSAT <20%

241 (39.1)

134 (43.8)

2 (0.3)

2 (0.7)

#ULN (4.9 mg/l)

457 (74.2)

223 (72.9)

>ULN (4.9 mg/l)

156 (25.3)

81 (26.5)

$60
Iron repletion status, n (%)

Missing
CRP,c n (%)

Missing

3 (0.5)

2 (0.7)

Mean (SD) total cholesterol, mg/dl

174.9 (48.4)

172.5 (52.5)

Mean (SD) LDL cholesterol, mg/dl

98.0 (39.1)

96.3 (40.0)

Hypertension

583 (94.6)

292 (95.4)

Diabetes mellitus

398 (64.6)

200 (65.4)

Stroke

56 (9.1)

26 (8.5)

CHF (NYHA 1 or 2)

51 (8.3)

24 (7.9)

MI (STEMI or NSTEMI)

31 (5.0)

21 (6.9)

CVD history, n (%)

BMI, body mass index; CHF, congestive heart failure; CRP, C-reactive protein; eGFR,
estimated glomerular ﬁltration rate; MI, myocardial infarction; NSTEMI, non-ST-segment
elevation myocardial infarction; NYSA, New York Heart Association; SAF, safety population; SD, standard deviation; STEMI, ST-segment elevation myocardial infarction;
TSAT, transferrin saturation; ULN, upper limit of normal.
a
Defined as the mean of up to 4 of the last central laboratory values before the first
dose.
b
Defined as the mean of all available central lab values before the first dose of study
drug, including the day-1 predose value.
c
Defined as the mean of values obtained within 2 weeks before the first dose.

treatment received was different from that randomly
assigned, the actual treatment received was analyzed.
Because TEAE and TESAE rates were expected to be
affected by between-group differences in discontinuation rates, exposure-adjusted incidence rates (patients
per 100 patient exposure years [PEY]) were calculated.
Descriptive statistics were used for all safety data
(TEAEs, TESAEs, and deaths).
Kidney International Reports (2021) 6, 624–635
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RESULTS
Patient Disposition and Baseline Characteristics
Between November 5, 2012, and September 24, 2018,
922 were randomized to receive oral roxadustat (n ¼
616) or placebo (n ¼ 306); 916 patients (611 and 305)
took $1 dose of medication. In the roxadustat group,
43.3% (267/616) of patients discontinued treatment,
whereas 68.0% (208/306) of placebo-treated patients
discontinued treatment (Figure 2). This between-group
difference in discontinuations was largely due to the
lack of efﬁcacy among patients in the placebo group.
The primary reasons for discontinuations in the placebo group were withdrawal of consent and lack of
efﬁcacy. The primary reasons for discontinuations in
the roxadustat group, which occurred at lesser rates
were adverse events or death and withdrawal of
consent.
Baseline characteristics were balanced between
groups (Table 1). Mean (SD) hemoglobin was 9.10 (0.75)
and 9.09 (0.69) g/dl, and mean eGFR levels were 21.9
(11.5) and 22.4 (11.4) ml/min per 1.73 m2, roxadustat
versus placebo, respectively. Approximately 32% of
patients had stage 5 CKD, and 40% of patients were not
iron replete (TSAT <20% or ferritin <100 ng/ml).
Treatment duration was up to 4.5 years. The median
duration of study drug exposure was 95.6 weeks in the
roxadustat group and 52.1 weeks in the placebo group,
resulting in an overall drug exposure three times
higher for roxadustat (1134.9 vs. 377.3 PEY). The differential dropout rate manifested as early as week 8. In
each baseline eGFR category, study drug discontinuation was higher in placebo- versus roxadustat-treated
patients. The relative difference in discontinuation
was most pronounced in those with the lowest eGFRs
(Figure 3). In patients with baseline eGFR <10 ml/min
per 1.73 m2, 40 of 71 roxadustat-treated patients versus
5 of 19 placebo-treated patients were still on treatment
at week 48.
Primary Efﬁcacy Endpoints
For the US primary endpoint, the mean (SD) hemoglobin change to weeks 28 to 52 regardless of rescue
therapy was larger in the roxadustat versus placebo
group. The least-squares mean (LSM) between-group
treatment difference (roxadustatplacebo) was 1.85 g/
dl (95% CI 1.74–1.97; P < 0.0001) (Figure 4a). Among
subgroups, the results were consistent (Supplementary
Figure S1).
For the EU primary endpoint, the proportion of
patients achieving a response without rescue therapy at
2 consecutive visits during the ﬁrst 24 weeks was
larger in the roxadustat versus placebo group (86.0%
[95% CI 83.0%–88.7%] vs. 6.6% [95% CI 4.1%–
627
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Figure 3. Percentage of patients on treatment over time by baseline estimated glomerular ﬁltration rate (eGFR) category (safety population [SAF]).

Secondary Efﬁcacy Endpoints
Mean (SD) change in hemoglobin over weeks 28 to 36
without rescue therapy within 6 weeks of and during
the 8-week treatment period were 2.02 (1.07) and 0.20
(0.99) g/dl in roxadustat and placebo groups. The LSM

9.9%]), with an odds ratio of 77.6 (95% CI 44.7–134.5;
P < 0.0001) (Figure 4b). Among subgroups, the results
were consistent (Supplementary Figure S2). The analyses using multiple imputations provided similar results in direction and magnitude.

a

Roxadustat (n = 608)

b

Placebo (n = 305)

Roxadustat (n = 608)
Paents Achieving a Hb Response (%)

12.5

Mean (SE) Hb Levels (g/dl)

12.0
11.5
11.0
10.5
10.0
9.5
9.0
8.5

90
80

4

8

12

20

28

32

36

40

44

48

Time (Weeks)
Changes in Hb (g/dl) from BL over W28–52 regardless of rescue therapy (ITT)
Roxadustat
Placebo
Treatment
Hb (O + I)
Hb ∆ from BL
Hb (O + I) Hb ∆ from BL Diﬀerence †
BL*
9.1 (0.8)
9.1 (0.7)
W28–52 11.1 (0.7)
2.00 (0.95)
9.2 (1.1)
0.16 (0.90)
LSM (SE)
2.02 (0.04)
0.17 (0.05)
1.85 (0.06)
(95% CI)
(1.95, 2.09)
(0.07, 0.27)
(1.74, 1.97)
P-value
<0.0001

52

76.2

82.1

78.6

83.4

84.7

85.5

86.0

72.2

70

66.6

60

55.1

50
40

35.2

30
20
9.7

10
0

0 1 2

Placebo (n = 305)

100

1.2 0.3

1

1.3

2

2.3

4

3.9

6

4.3

8

4.3

10

4.9

12

4.9

14

5.2

16

5.6

18

6.2

20

6.2

22

6.6

24

Week
Paents Achieving a Hb Response during ﬁrst 24 weeks of treatment, censoring for rescue therapy (FAS)
Diﬀerence
OR (95% CI)‡
Roxadustat Placebo
(95% CI)
[Roxadustat/Placebo]
20 (6.6) 79.5 (75.6, 83.4)
77.6 (44.7, 134.5)
Paents Achieving Response‡, n (%) 523 (86.0)
§
(83.0, 88.7)
(4.1, 9.9)
(95% CI)
||
P-value
<0.0001

Figure 4. Hemoglobin levels over time (a) and percentage of patients with a hemoglobin response (b). *Deﬁned as the mean of up to 4 last central
laboratory values before the ﬁrst dose of study treatment. †Multiple imputation strategy by combining the results of ANCOVA model with baseline Hb
and baseline eGFR as covariates, and treatment and other randomization stratiﬁcation factors, except baseline Hb (#8 vs. >8 g/dl) and eGFR (<30
vs. $30 ml/min per 1.73 m2), as fixed effects. ‡Patient who achieved Hb response (central laboratory values: Hb $11.0 g/dl and an Hb increase from
baseline by $1.0 g/dl in patients with baseline Hb >8 g/dl, or an increase in Hb $2.0 g/dl in patients with baseline Hb #8 g/dl) at 2 consecutive
visits $5 days apart during the first 24 weeks of treatment without rescue therapy. Patients who dropped out or received rescue therapy before or on
the date of the second consecutive Hb value were classified as nonresponders. §Based on the exact method of Clopper-Pearson. ||CMH method
adjusting for all randomization stratification factors. D, change; ANCOVA, analysis of covariance; CMH, Cochran-Mantel-Haenszel; CI, confidence
interval; eGFR, estimated glomerular filtration rate; FAS, full analysis set; Hb, hemoglobin; I, imputed; ITT, intent to treat; LS, least squares; O, observed;
SE, standard error; W, weeks.
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Roxadustat (n=608)

Placebo (n=305)

Mean (SD) LDL Cholesterol (mg/dl)

100
95
90
85
80
75
70
65
60
0

4

8

12

20

28

36

44

52

Time (Weeks)

Figure 5. Low-density lipoprotein (LDL) cholesterol levels over time (full analysis set).

between-group treatment difference was 1.88 g/dl
(95% CI 1.73–2.04; P < 0.0001).
Mean (SD) changes from baseline in hemoglobin over
weeks 28 to 52 in roxadustat and placebo patients with
baseline high-sensitivity C-reactive protein greater
than the upper limit of normal were 2.02 (0.93) and 0.18
(0.95) g/dl, with a LSM difference of 1.90 g/dl (95% CI
1.66–2.14; P < 0.0001).
The proportion of patients with hemoglobin $10.0
g/dl over weeks 28 to 36 without rescue therapy within
6 weeks of and during the 8-week treatment period was
larger in the roxadustat versus placebo group (76.8%
[95% CI 73.2%–80.1%] vs. 18.4% [95% CI 14.2%–
23.2%]), with an odds ratio of 15.5 (95% CI 10.79–
22.19; P < 0.0001).
Roxadustat lowered mean LDL cholesterol at week 4,
and this was sustained through week 52 (Figure 5). The
mean (SD) change from baseline in LDL cholesterol over
weeks 12 to 28 was 18.48 (29.60) in the roxadustat
group and 0.22 (29.37) mg/dl in the placebo group,
corresponding to an LSM difference of 17.26 mg/dl
(95% CI 20.65 to 13.87; P < 0.0001). The LDL
cholesterol-lowering effect of roxadustat was similar in
patients taking or not taking statins (Supplementary
Table S4).
A smaller proportion of patients in roxadustat
versus placebo groups received rescue therapy during
the ﬁrst 52 weeks (8.9% vs. 28.9%) with a hazard ratio
of 0.19 (95% CI 0.14–0.28; P < 0.0001) (Figure 6a). The
percentage of patients receiving RBC transfusion during the ﬁrst 52 weeks of treatment was lower in the
roxadustat versus placebo group (5.6% and 15.4%),
with a time to ﬁrst rescue therapy use hazard ratio of
0.26 (95% CI 0.17–0.41; P < 0.0001 [nominal])
(Figure 6b). The percentage of patients who received
i.v. iron therapy was lower in the roxadustat versus
placebo group (2.5% vs. 4.9%), with a time to ﬁrst i.v.
iron use hazard ratio of 0.39 (95% CI 0.19–0.81) (P ¼
0.011). The percentage of patients who received ESA
Kidney International Reports (2021) 6, 624–635

therapy was lower in the roxadustat versus placebo
group (2.1% vs. 6.7%), with a time to ﬁrst ESA therapy hazard ratio of 0.08 (95% CI 0.04–0.15) (P <
0.0001).
Mean (SD) changes from baseline in the Short
Form-36 Vitality subscore averaged over weeks 12 to
28 were 1.90 (8.71) and 1.02 (8.33) points in the
roxadustat and placebo groups, corresponding to a
LSM difference of 1.22 points (95% CI 0.15–2.29; P ¼
0.0259).
There was no signiﬁcant between-group difference
in progression of CKD, as measured by the rate of
change in eGFR over time. Therefore, the ﬁxedsequence testing was stopped.
Additional Efﬁcacy Endpoints
The mean (SD) change from baseline in hemoglobin
averaged over weeks 28 to 36 by baseline iron status in
the roxadustat group was 2.07 (1.03) g/dl among those
with baseline ferritin <100 ng/ml and/or TSAT <20%
versus 1.99 (1.04) g/dl in those with baseline
ferritin $100 ng/ml and TSAT $20%. Both of these
results were signiﬁcantly higher than the corresponding values in the placebo group (0.37 [1.05] vs. 0.02
[0.88] g/dl) (P < 0.0001).
At baseline, mean (SD) hepcidin levels were comparable in the roxadustat and placebo groups (110.66
[79.08] and 106.11 [90.68] mg/l). Roxadustat-treated
patients experienced a lowering in serum hepcidin at
week 4, which was sustained through week 44
(Figure 7a). Mean (SD) changes from baseline to week
44 in the roxadustat and placebo groups were 22.11
(80.90) and 3.88 (80.9) mg/l with an LSM difference
of 25.71 mg/l (95% CI 38.52 to 12.90)
(Supplementary Table S5).
At baseline, mean (SD) ferritin levels were comparable in the roxadustat and placebo groups (306.89
[388.48] and 308.39 [352.51] ng/ml; Supplementary
Table S5). Through week 12, roxadustat-treated
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Figure 6. Time from baseline to ﬁrst use of rescue therapy (a) and ﬁrst blood/RBC transfusion (b). Time to ﬁrst event was calculated as: (ﬁrst
event date or censoring date  ﬁrst dose date þ 1)/7. Patients were censored at last dose, week 52, last visit date, or death date, whichever
occurred ﬁrst, if rescue therapy after the ﬁrst 52 weeks did not occur. Rescue therapy was deﬁned as any use of RBC transfusion, ESA, or i.v.
iron. Cox proportional hazards model adjusted for baseline Hb, eGFR, and other randomization stratiﬁcation factors, except baseline Hb (#8.0 vs.
>8.0 g/dl) and eGFR (<30 vs. $30 ml/min per 1.73 m2). eGFR, estimated glomerular filtration rate; ESA, erythropoiesis-stimulating agent; Hb,
hemoglobin; i.v., intravenous; RBC, red blood cell.

patients experienced a decrease in ferritin that returned
toward baseline by week 20 (Figure 7b).
At baseline, mean (SD) serum iron was comparable in
the roxadustat and placebo groups (65.42 [25.05] and
66.26 [26.02] mg/dl; Supplementary Table S5). In
roxadustat-treated patients, mean serum iron decreased
from baseline to week 4, and then increased above
baseline by 10.4 mg/dl through week 20, remaining
stable through week 52 (Figure 7c). At baseline, mean
(SD) TIBC also was comparable in the roxadustat and
630

placebo groups (257.18 [50.51] and 262.30 [49.64
mg/dl]). By week 44, TIBC increased in the roxadustat
group and decreased in placebo group, with a LSM
difference of 38.65 (95% CI 31.86–45.45; P < 0.0001)
(Supplementary Table S5).
At baseline, TSAT was 26% in both groups. In
the roxadustat group, mean TSAT initially decreased
from baseline up to weeks 4 through 8, and then
gradually increased and plateaued after week 20
(Figure 7d).
Kidney International Reports (2021) 6, 624–635
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Figure 7. Levels of hepcidin (a), ferritin (b), iron (c), and TSAT (d) (full analysis set). SE, standard error; TSAT, transferrin saturation.

Total cholesterol and LDL/high-density lipoprotein
ratios were reduced over time. For total cholesterol,
mean (SD) changes from baseline to week 52 in roxadustat and placebo groups were 27.20 (45.79)
and 3.21 (49.78) mg/dl. For the LDL/high-density lipoprotein ratio, mean (SD) changes from baseline to
week 52 in roxadustat and placebo groups were 0.19
(0.91) and 0.10 (0.79) mg/dl.
Tolerability
TEAEs were reported by 92.3% (564/611) of roxadustatand 89.5% (273/305) of placebo-treated patients, corresponding to incidence rates of 554.4 and 594.5/100 PEY.
The most common TEAEs in the roxadustat or placebo
group were hyperkalemia (13.6 vs. 12.5/100 PEY), constipation (12.2 vs. 10.3/100 PEY), viral upper respiratory
tract infection (16.9 vs. 15.4/100 PEY), upper respiratory
tract infection (12.8 vs. 18.0/100 PEY), and hypertension
(11.3 vs. 10.1/100 PEY) (Table 2). The incidence rates of
TESAEs were 74.2 and 66.0/100 PEY among roxadustatversus placebo-treated patients (Table 3). Incidence rates
for fatal TESAEs were 3.8 and 2.9, respectively.
Through 52 weeks of treatment, the incidence of
TEAEs was comparable in roxadustat- and placebotreated patients (87.6% and 85.9%), corresponding to
incidence rates of 643.4 and 684.0, respectively. TEAEs
occurring in $5% of patients in either treatment group
are summarized in Supplementary Table S6. The
Kidney International Reports (2021) 6, 624–635

incidence of TESAEs through 52 weeks of treatment
was also comparable (33.2% and 29.8%), and TESAEs
occurring in $1% of patients in either treatment group
are summarized in Supplementary Table S7. Time-todeath analyses at various time points (52 weeks, 104
weeks, up to 28 days after the last dose of study drug,
and including deaths during long-term follow-up)
suggest there was no signiﬁcant difference in mortality
risk between the 2 groups.
DISCUSSION
In this ANDES Phase 3 study, roxadustat administered
orally 3 times per week was superior to placebo in
correcting and maintaining hemoglobin levels in patients with NDD-CKD and CKD-related anemia, with a
comparable overall tolerability proﬁle. Signiﬁcant and
comparable improvements in hemoglobin were
observed in the iron-replete and not iron–replete subgroups (baseline ferritin <100 ng/l and/or
TSAT <20%). Inﬂamed patients, reﬂected by high
high-sensitivity C-reactive protein levels, are more
likely to be ESA hyporesponsive and require higher
ESA doses or have lower hemoglobin. In contrast, we
found no signiﬁcant differences in hemoglobin
response or roxadustat dose in the subgroups with
normal versus elevated high-sensitivity C-reactive
protein levels. Nevertheless, these results should be
interpreted in light of the fact that hyporesponsiveness
631
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Table 2. Summary of TEAEsa occurring in $5% of patients in either treatment group (OTþ28) (SAF)
Roxadustat (n [ 611)

Placebo (n [ 305)

n (%)

PEY [ 1134.9 events (per 100 PEY)

n (%)

PEY [ 377.3c events (per 100 PEY)

Hyperkalemia

111 (18.2)

154 (13.6)

41 (13.4)

47 (12.5)

Constipation

105 (17.2)

139 (12.2)

34 (11.1)

39 (10.3)

Viral upper respiratory tract infection

98 (16.0)

192 (16.9)

40 (13.1)

58 (15.4)

Hypertension

95 (15.5)

128 (11.3)

27 (8.9)

38 (10.1)

Preferred term

b

c

Edema peripheral

89 (14.6)

128 (11.3)

28 (9.2)

38 (10.1)

Nausea

85 (13.9)

110 (9.7)

29 (9.5)

35 (9.3)

Upper respiratory tract infection

79 (12.9)

145 (12.8)

48 (15.7)

68 (18.0)

Diarrhea

78 (12.8)

106 (9.3)

31 (10.2)

39 (10.3)

Urinary tract infection

68 (11.1)

103 (9.1)

29 (9.5)

56 (14.8)

End-stage renal disease

67 (11.0)

74 (6.5)

18 (5.9)

18 (4.8)

Headache

66 (10.8)

99 (8.7)

26 (8.5)

31 (8.2)

Insomnia

63 (10.3)

75 (6.6)

9 (3.0)

10 (2.7)

Dizziness

58 (9.5)

85 (7.5)

32 (10.5)

35 (9.3)

Cough

57 (9.3)

71 (6.3)

28 (9.2)

33 (8.7)

Back pain

55 (9.0)

66 (5.8)

18 (5.9)

20 (5.3)

Chronic kidney disease

54 (8.8)

61 (5.4)

21 (6.9)

22 (5.8)

Pruritus

54 (8.8)

72 (6.3)

19 (6.2)

24 (6.4)

Vomiting

54 (8.8)

65 (5.7)

20 (6.6)

22 (5.8)

Hypoglycemia

53 (8.7)

69 (6.1)

15 (4.9)

17 (4.5)

Acute kidney injury

49 (8.0)

55 (4.8)

11 (3.6)

13 (3.4)

Edema

48 (7.9)

62 (5.5)

9 (3.0)

12 (3.2)

Arthralgia

45 (7.4)

50 (4.4)

24 (7.9)

27 (7.2)

Pneumonia

44 (7.2)

52 (4.6)

18 (5.9)

21 (5.6)

Decreased appetite

41 (6.7)

51 (4.5)

8 (2.6)

8 (2.1)

Muscle spasms

41 (6.7)

53 (4.7)

9 (3.0)

10 (2.7)

Hyperphosphatemia

40 (6.5)

46 (4.1)

10 (3.3)

10 (2.7)

Dyspepsia

39 (6.4)

45 (4.0)

12 (3.9)

12 (3.2)

Pain in extremity

39 (6.4)

42 (3.7)

14 (4.6)

14 (3.7)

Pyrexia

39 (6.4)

61 (5.4)

9 (3.0)

12 (3.2)

Abdominal pain

35 (5.7)

44 (3.9)

13 (4.3)

14 (3.7)

Bronchitis

34 (5.6)

44 (3.9)

13 (4.3)

16 (4.2)

Dyspnea

34 (5.6)

49 (4.3)

23 (7.5)

28 (7.4)

Cellulitis

32 (5.2)

37 (3.3)

7 (2.3)

22 (5.8)

Gout

32 (5.2)

46 (4.1)

20 (6.6)

33 (8.7)

Asthenia

31 (5.1)

35 (3.1)

11 (3.6)

11 (2.9)

Hypotension

31 (5.1)

37 (3.3)

10 (3.3)

10 (2.7)

Metabolic acidosis

29 (4.7)

31 (2.7)

18 (5.9)

20 (5.3)

Anemia

17 (2.8)

19 (1.7)

44 (14.4)

58 (15.4)

AE, adverse event; OT, on treatment; PEY, patient exposure year; SAF, safety population; TEAE, treatment-emergent adverse event.
a
Occurred after the first dose of study drug and up to 28 days after the last dose was considered a TEAE if it was not present before the first dose of study drug, or it was present before
the first dose of study drug but increased in severity during the double-blind treatment period. Patients with >1 event in a category were counted only once for that category.
b
MedDRA (Medical Dictionary for Regulatory Activities) version 20.0.
c
PEY ¼ (Last Dose Date  First Dose Date þ 1) / 365.25.

to ESAs is a complex topic with both acute and chronic
effects. Our ﬁndings may reﬂect the effect of roxadustat in patients who could be hyporesponsive to ESAs
to the extent that C-reactive protein is a surrogate for
the hyporesponsive state.
Roxadustat reduced the use of RBC transfusion. RBC
transfusions may result in complications such as volume overload, hyperkalemia, immunologically mediated transfusion reactions, iron overload, and in rare
cases, transmission of infections.5 In addition, signiﬁcant costs are associated with RBC transfusions,
including storage and acquisition.24 Importantly,
because of alloimmunization risks, RBC transfusion can
632

decrease the opportunity to receive a kidney transplant. Reducing the need for transfusions with roxadustat may reduce the associated risks, lower health
care costs, and preserve the opportunity for
transplantation.
Roxadustat reduced mean LDL cholesterol in all
patients regardless of whether they were taking statins.
The LDL cholesterol-lowering effect may be mediated
by HIF-dependent effects on acetyl coenzyme A that
are required for the ﬁrst step of cholesterol synthesis,25
and on the degradation of 3-hydroxy-3-methylglutaryl
coenzyme A reductase, the rate-limiting enzyme in
cholesterol synthesis.26,27 This may be beneﬁcial, as
Kidney International Reports (2021) 6, 624–635
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Table 3. Summary of TESAEsa occurring in $2% of patients in either treatment group (OTþ28) (SAF)
Roxadustat (n [ 611)

Placebo (n [ 305)

n (%)

PEY [ 1134.9 events (/100 PEY)

Acute kidney injury

41 (6.7)

45 (4.0)

6 (2.0)

7 (1.9)

End-stage renal disease

34 (5.6)

36 (3.2)

10 (3.3)

10 (2.7)

Pneumonia

29 (4.7)

35 (3.1)

12 (3.9)

13 (3.4)

Chronic kidney disease

27 (4.4)

30 (2.6)

9 (3.0)

9 (2.4)

Cardiac failure congestive

23 (3.8)

25 (2.2)

5 (1.6)

5 (1.3)

Hyperkalemia

19 (3.1)

22 (1.9)

4 (1.3)

4 (1.1)

Urinary tract infection

18 (2.9)

21 (1.9)

8 (2.6)

10 (2.7)

Hyponatremia

15 (2.5)

16 (1.4)

3 (1.0)

3 (0.8)

Azotemia

13 (2.1)

13 (1.1)

5 (1.6)

5 (1.3)

Hypoglycemia

13 (2.1)

14 (1.2)

4 (1.3)

4 (1.1)

Peritonitis

b

Preferred Term

c

n (%)

PEY [ 377.3c Events (/100 PEY)

13 (2.1)

14 (1.2)

1 (0.3)

1 (0.3)

Anemia

5 (0.8)

5 (0.4)

8 (2.6)

8 (2.1)

Pulmonary edema

4 (0.7)

5 (0.4)

6 (2.0)

7 (1.9)

OT, on treatment; PEY, patient exposure year; SAF, safety population; TESAE, treatment-emergent serious adverse event.
a
Occurred after the first dose of study drug and up to 28 days after the last dose of study drug was considered a treatment-emergent adverse event (TEAE) if it was not present before
the first dose of study drug, or it was present before the first dose of study drug but increased in severity during the double-blind treatment period. An adverse event that occurred more
than 28 days after the last dose of study drug was not counted as a TEAE. Patients with >1 event in a category were counted only once for that category.
b
MedDRA (Medical Dictionary for Regulatory Activities) version 20.0.
c
PEY ¼ (Last Dose Date  First Dose Date þ 1) / 365.25; reported as an event rate per 100 PEY.

patients with CKD are more likely to die from cardiovascular events28 than from kidney failure.
Hepcidin regulates iron absorption and mobilization
of iron from hepatocytes and macrophages. Hepcidin is
downregulated by hypoxia via HIF stabilization, which
increases the synthesis of iron transport proteins and
intestinal iron absorption,29,30 and improves the release
of macrophage iron onto transferrin.31 Serum hepcidin
levels decreased with roxadustat, which was likely due
to indirect effects, including the production of erythroferrone by developing erythroblasts and normoblasts, as well as utilization of iron for hemoglobin
synthesis. This study conﬁrms the ﬁndings of previous
clinical trials in patients with NDD-CKD demonstrating
that roxadustat increased hemoglobin levels while
maintaining stable serum iron levels, despite robust
erythropoiesis, without i.v. iron.34,35
TSAT is a ratio of serum iron and TIBC. Although
TSAT values were stable in the roxadustat and placebo
groups, there was a between-group difference in the
constituent components of the calculation. In the placebo group, neither serum iron nor TIBC changed. In
the roxadustat group, both serum iron and TIBC34
increased, suggesting greater iron movement through
transferrin for erythropoiesis. Ferritin, which reﬂects
intracellular iron stores and inﬂammation, decreased in
parallel to the decline in hepcidin and the rise in serum
iron. This suggests roxadustat may help mobilize iron
stores previously sequestered by hepcidin and
inﬂammation.
Largely due to worsening anemia, signiﬁcantly more
patients in the placebo group discontinued study
participation than the roxadustat group. This is
Kidney International Reports (2021) 6, 624–635

supported by the reasons behind discontinuation. This
led to a signiﬁcant difference in median drug exposure
time between the groups, and was most pronounced in
patients with the lowest baseline eGFR. The risks of
morbidity and mortality and anemia severity increase
as eGFR decreases, which leads to higher discontinuations in the placebo group. Thus, informative
censoring may have affected the comparison between
treatment groups for events such as acute kidney
injury and end-stage renal disease. To reduce the effect
of this bias, we provide exposure-adjusted comparisons
of incidence rates for adverse events. Overall, incidence
rates of the most commonly reported TEAEs and
TESAEs were comparable between treatment groups.
As part of the sensitivity analyses, these data also were
evaluated during the ﬁrst 52 weeks of treatment when
the between-group differences in exposure were less
disparate.
The design and results of this study should be
considered relative to the current standard of care for
patients with NDD-CKD. Since the completion of
CHOIR,8 CREATE,6 and TREAT,7 the proportion of
patients treated for anemia has declined. In 2003,
approximately 33% of patients received an ESA in the
year before starting chronic dialysis. Largely because
of ESA safety concerns, predialysis treatment with an
ESA had declined to <14% by 2014.35 Therefore, the
use of placebo as a comparator more accurately reﬂects
the current standard of care. A placebo control also
provides a clearer assessment of the safety of roxadustat and its novel mechanism of action.
This trial had a larger proportion of patients with
stage 4 to 5 CKD than other anemia trials. Although the
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mean baseline eGFRs for patients in CHOIR and TREAT
were approximately 27 and 34 ml/min per 1.73 m2, the
mean in this study was 22 ml/min per 1.73 m2, and
32% of these patients had stage 5 CKD. This allows for
the assessment of efﬁcacy and safety in a population
not previously studied with ESAs.
This Phase 3 clinical study evaluating the efﬁcacy
and safety of roxadustat versus placebo in patients
with NDD-CKD and anemia included patients with
more advanced CKD, more severe anemia, less iron
repletion at baseline, and less concomitant i.v. iron use,
compared with previous studies in this population.
Treatment with roxadustat versus placebo met both
primary efﬁcacy endpoints, was superior to placebo for
increasing hemoglobin, and reduced the need for
blood/RBC transfusion. The overall exposure-adjusted
safety proﬁle of roxadustat was comparable to placebo and consistent with that expected in patients with
CKD-related anemia.
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